NCT05876715View on ClinicalTrials.gov

LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Advanced Soft-tissue Sarcoma
Interventions
DRUG

Lurbinectedin

This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.

Trial Locations (1)

90403

RECRUITING

Sarcoma Oncology Research Center, Santa Monica

All Listed Sponsors
lead

ERLINDA M GORDON

OTHER